FINHUB Insights

EW · Q2 FY25 · Apr 1 – Jun 30, 2025

Edwards Lifesciences Q2 FY25: where the revenue came from and where it went

Edwards Lifesciences Q2 FY25: revenue $1.5B (+12% year over year). Net profit $0.3B. Largest cohort Transcatheter Aortic Valve… $1.1B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 6, 2025 10-Q
Sankey diagram of Edwards Lifesciences's income statement for Q2 FY25: revenue of $1.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.5B +12% year over year
Gross profit$1.2B 78% margin
Operating profit$0.4B 27% margin
Net profit$0.3B 22% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 1.5 100% +12%
Transcatheter Aortic Valve… 1.1 73% +9%
Surgical Heart Valve Therapy 0.3 20% +8%
Transcatheter Mitral and… 0.1 7% +62%
Cost of revenue−0.320%
Gross profit1.278% margin−2pp
Research & development−0.318%−2pp
SG&A−0.533%+0pp
Operating profit0.427% margin+0pp
Tax−0.1
Net profit0.322%−5pp
Filing on EDGAR More quarters of EW

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters